Clinical Trials
Fast Facts
Our clinical trials portfolio includes:
- More than 40 research studies
- More than 10 Pediatric-focused studies
- Five phase-1 Trials
- First-In-Human treatments
- Investigational New Drugs developed at UF
Featured Trial
BRAVO
Patients in this study will either receive concurrent TMZ during RT and immunotherapy during and after maintenance cycles of dose-intensive TMZ (Group A) or focal radiotherapy alone and immunotherapy without maintenance DI TMZ (Group B). Immune responses during cycles of DC vaccination with or without DI TMZ will be evaluated in both treatment groups.
Subject inclusion criteria:
- Age: 3 to 21 years old
- Radiologically confirmed DIPG and patient and/or parents/guardian willing to consent to biopsy
- performance status
- Bone Marrow, Renal and Hepatic tests
Read more about the BRAVO Clinical Trial
Contact Marcia Hodik to hear more about the BRAVO Clinical Trial.
Browse or search current neurosurgery clinical trials
PNOC-001
Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children
PNOC-005
A Phase 1 Study of Modified Measles Virus (MV-NIS) for the Treatment of Children and Young Adults with Recurrent Medulloblastoma or Recurrent Atypical Teratoid Rhabdoid Tumors (ATRT)
ACTION
Adoptive Cellular Therapy following Dose-Intensified Temozolomide in Newly-diagnosed Pediatric High-grade Gliomas
Coordinator
HeadStart 4
Newly Diagnosed Children (Less than 10 Years Old) With Medulloblastoma and Other Central Nervous System Primitive Neuro-Ectodermal Tumors: Clinical and Molecular Risk-Tailored Intensive and Compressed Induction Chemotherapy Followed by Consolidation with Either Single-Cycle (Low Risk Patients) or Randomization (High Risk Patients) to either Single-Cycle or to Three Tandem Cycles of Marrow-Ablative Chemotherapy with Autologous Hematopoietic Progenitor Cell Rescue
BRAVO
BRAVO: Newly-Diagnosed Brain Stem Gliomas Treated with Adoptive Cellular Therapy during Recovery from Focal Radiotherapy Alone or Radiotherapy and Dose-intensified Temozolomide
Coordinator